Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 booster immunogenicity comparison of S-268019 versus COMIRNATY in children aged 5 to 11 years
jRCT2031220530Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing S-268019 booster with COMIRNATY booster (2 arms). Primary endpoints: Geometric mean titer of SARS-CoV-2 neutralizing antibodies on Day 29 and Seroresponse rate of SARS-CoV-2 neutralizing antibodies on Day 29. Started Jan 2023; status: completed.
02
Drugs
S-268019-btozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031220530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220530.